Abstract:Background: Epigenetic gene silencing is one of the major causes of carcinogenesis. Its widespread occurrence in cancer genome could inactivate many cellular pathways including DNA repair, cell cycle control, apoptosis, cell adherence, and detoxification. The abnormal promoter methylation might be a potential molecular marker for cancer management.Methods: For rapid identification of potential targets for aberrant methylation in gynecological cancers, methylation status of the CpG islands of 34 genes was determined using pooled DNA approach and methylation-specific PCR. Pooled DNA mixture from each cancer type (50 cervical cancers, 50 endometrial cancers and 50 ovarian cancers) was made to form three test samples. The corresponding normal DNA from the patients of each cancer type was also pooled to form the other three control samples. Methylated alleles detected in tumors, but not in normal controls, were indicative of aberrant methylation in tumors. Having identified potential markers, frequencies of methylation were further analyzed in individual samples. Markers identified are used to correlate with clinico-pathological data of tumors using chi(2) or Fisher's exact test.Results: APC and p16 were hypermethylated across the three cancers. MINT31 and PTEN were hypermethylated in cervical and ovarian cancers. Specific methylation was found in cervical cancer (including CDH1, DAPK, MGMT and MINT2), endometrial cancer (CASP8, CDH13, hMLH1 and p73), and ovarian cancer (BRCA1, p14, p15, RIZ1 and TMS1). The frequencies of occurrence of hypermethylation in 4 candidate genes in individual samples of each cancer type (DAPK, MGMT, p16 and PTEN in 127 cervical cancers; APC, CDH13, hMLH1 and p16 in 60 endometrial cancers; and BRCA1, p14, p16 and PTEN in 49 ovarian cancers) were examined for further confirmation. Incidence varied among different genes and in different cancer types ranging from the lowest 8.2% (PTEN in ovarian cancer) to the highest 56.7% (DAPK in cervical cancer). Aberrant methylation for some genes (BRCA1, DAPK, hMLH1, MGMT, p14, p16, and PTEN) was also associated with clinico-pathological data.Conclusion: Thus, differential methylation profiles occur in the three types of gynecologic cancer. Detection of methylation for critical loci is potentially useful as epigenetic markers in tumor classification. More studies using a much larger sample size are needed to define the potential role of DNA methylation as marker for cancer management.

The Identification of Specific Methylation Patterns across Different Cancers

Identification of the Differential DNA Methylation Markers among Cancers

Identification of cancer DNA methylation regulatory sites

DNA Methylation Markers for Diagnosis and Prognosis of Common Cancers.

Comparative Pan-Cancer DNA Methylation Analysis Reveals Cancer Common and Specific Patterns.

Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis

An analysis about heterogeneity among cancers based on the DNA methylation patterns

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer

Identification of Regulatory Role of DNA Methylation in Colon Cancer Gene Expression Via Systematic Bioinformatics Analysis

Differential Methylation Relative to Breast Cancer Subtype and Matched Normal Tissue Reveals Distinct Patterns

Exploring Epigenetic Biomarkers of Universal Specificities and Commonalities among Pan-Cancer Cohorts in the Cancer Genome Atlas.

Differential DNA Methylation Profiles in Gynecological Cancers and Correlation with Clinico-Pathological Data

DNA methylation profiles capturing breast cancer heterogeneity

Discriminating Origin Tissues of Tumor Cell Lines by Methylation Signatures and Dys-Methylated Rules

Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients

Identifying CpG Sites with Different Differential Methylation Frequencies in Colorectal Cancer Tissues Based on Individualized Differential Methylation Analysis

Screening Dys-Methylation Genes and Rules for Cancer Diagnosis by Using the Pan-Cancer Study

Uncoordinated expression of DNA methylation-related enzymes in human cancer

A Hybrid Ensemble Approach for Identifying Robust Differentially Methylated Loci in Pan-Cancers

Identifying Methylation Pattern And Genes Associated With Breast Cancer Subtypes

MethyCancer: the Database of Human DNA Methylation and Cancer